A study published in Circulation showed that the Apple Watch’s ECG detected some arrhythmias other than atrial fibrillation. The device is currently cleared to take ECGs and general irregular pulse alerts, which could indicate potential cases of atrial fibrillation.
A study published in August found that women experienced more adverse events from Boston Scientific’s Watchman implant than men. The FDA said it plans to take a closer look at data for these stroke-prevention implants, but still says the benefits outweigh the risks.
UK researchers have used artificial intelligence (AI) to develop a way to identify patients with heart failure who would benefit from treatment with beta blockers, by interrogating data from nine landmark clinical trials. The study applied machine learning to trial data involving 15,659 patients who were being treated for heart failure with reduced ejection fraction …
AI could be used to guide drug therapy for heart failure Read More »
An artificial intelligence algorithm already shown to be able to detect atrial fibrillation (AF) in clinical testing has also shown its worth in a real-world setting, according to its developers. The AI – developed by the Bristol Myers Squibb-Pfizer Alliance on cardiovascular disease – was developed using machine learning from a UK dataset of almost …
Real-world study suggest AI may improve atrial fibrillation screening Read More »
Shots: The head-to-head Amulet IDE study compares Amplatzer Amulet Left Atrial Appendage (LAA) Occluder with the Watchman device to treat patients with AFib at an increased risk of stroke The study demonstrated superiority for the 1EPs of LAA (98.9% vs 96.8%) and was non-inferior for the co-primary safety & effectiveness endpoints Abbott’s Amulet Occluder with …
Abbott Laboratories received FDA approval for its Amulet device to treat people with atrial fibrillation who are at risk of ischemic stroke. The device would go head-to-head with one developed by Boston Scientific that was approved in 2015.
The digital health company filed a complaint with the Federal Trade Commission last week, seeking a ban on the import of the Apple Watch. AliveCor cited copyright violations related to Apple’s ECG feature as the reason for seeking the ban.
MedLumics has raised another €18 million (around $22 million) to fund clinical trials of its optically-guided imaging system used to guide a surgical procedure for atrial fibrillation (AF) – a serious heart condition that causes an irregular heartbeat. The Spanish biotech says the latest round – which comes after a $3.8 million first round in …
MedLumics raises €18 million for atrial fibrillation device Read More »
Update on Heart Rhythm Detection Devices for Remote Patient Monitoring Advances in the detection of heart rhythms using medical-grade but consumer-facing remote patient monitoring – product reviews The Doctor Weighs In
Update on Heart Rhythm Detection Devices for Remote Patient Monitoring Top Product Reviews: Advances in the detection of heart rhythms using medical-grade but consumer-facing remote patient monitoring. The Doctor Weighs In
A heart monitor developed by iRhythm has become the first product to be endorsed by NICE in a pilot project covering digital health technologies. In new guidance, the health technology assessment (HTA) agency has recommended iRhythm’s Zio XT service for detecting abnormal heart rhythms – provided NHS organisations that deploy it collect evidence of its …
iRhythm digital heart monitoring service backed by NICE Read More »
What You Should Know: – AliveCor announced they received FDA clearance of new algorithms for use with their personal EKG devices, KardiaMobile and KardiaMobile 6L. These additional determinations will be available via a software upgrade for the Kardia devices in 2021. – The additional FDA-cleared algorithms double the number of heart rhythm disturbances that AliveCor’s …
AliveCor Receives FDA Clearance of Next-Gen EKG Algorithms Read More »
What You Should Know: – Cardiopulmonary digital health company Eko raises $65M in Series C funding to close the gap between virtual and in-person heart and lung care. – The latest round of funding will enable Eko to expand in-clinic use of its platform of telehealth and AI algorithms for disease screening and to launch …
What You Should Know: – Cardiac patients and their cardiologists are experiencing a high number of false positives with remote patient monitoring devices as a result of signal artifact providing inaccurate data, which can lead to many complications—other than medical, such as unnecessary tests and increased medical costs. – Ambulatory cardiac monitoring provider InfoBionic has …
UK-based RHYTHM AI is to go ahead with a larger clinical trial of its artificial intelligence (AI)-driven system, which could be used as a treatment for atrial fibrillation without the need for medication. Antiarrhythmic drugs are standard therapy but they often only work for around 18 months, after which time a catheter ablation procedure is …
RHYTHM AI cleared for large trial of atrial fibrillation mapping tool Read More »
Fitbit’s new, $330 smartwatch has a slew of new features, including a wrist-based temperature sensor and a sensor to monitor stress.
What You Should Know: – Eko today announced a global collaboration with AstraZeneca to accelerate the development of digital health tools for the earlier screening of cardiovascular diseases, including heart failure. – Through the collaboration, AstraZeneca and Eko will explore accelerating the development of Eko algorithms, enhancing clinical trials with Eko technology, and potentially building …
AstraZeneca, Eko Collaborate to Advance Innovation Around Heart Failure Read More »
What You Should Know: – The National Institutes of Health (NIH) has granted next-generation cardiac AI company Eko an award totaling $2.7 million to support continued collaborative work with Northwestern Medicine Bluhm Cardiovascular Institute – The grant will focus on validating algorithms and help more accurately screen for heart murmurs and valvular heart disease during …
English
Afrikaans
Shqip
አማርኛ
العربية
Հայերեն
Azərbaycan dili
Euskara
Беларуская мова
বাংলা
Bosanski
Български
Català
Cebuano
Chichewa
简体中文
繁體中文
Corsu
Hrvatski
Čeština
Dansk
Nederlands
Esperanto
Eesti
Filipino
Suomi
Français
Frysk
Galego
ქართული
Deutsch
Ελληνικά
ગુજરાતી
Kreyol ayisyen
Harshen Hausa
Ōlelo Hawaiʻi
עִבְרִית
हिन्दी
Hmong
Magyar
Íslenska
Igbo
Bahasa Indonesia
Gaelige
Italiano
日本語
Basa Jawa
ಕನ್ನಡ
Қазақ тілі
ភាសាខ្មែរ
한국어
كوردی
Кыргызча
ພາສາລາວ
Latin
Latviešu valoda
Lietuvių kalba
Lëtzebuergesch
Македонски јазик
Malagasy
Bahasa Melayu
മലയാളം
Maltese
Te Reo Māori
मराठी
Монгол
ဗမာစာ
नेपाली
Norsk bokmål
پښتو
فارسی
Polski
Português
ਪੰਜਾਬੀ
Română
Русский
Samoan
Gàidhlig
Српски језик
Sesotho
Shona
سنڌي
සිංහල
Slovenčina
Slovenščina
Afsoomaali
Español
Basa Sunda
Kiswahili
Svenska
Тоҷикӣ
தமிழ்
తెలుగు
ไทย
Türkçe
Українська
اردو
O‘zbekcha
Tiếng Việt
Cymraeg
isiXhosa
יידיש
Yorùbá
Zulu